End-of-day quote
Shenzhen S.E.
06:00:00 2024-06-27 pm EDT
5-day change
1st Jan Change
21.16
CNY
-0.52%
-5.11%
-41.40%
Wuhan Hiteck Biological Pharma Co., Ltd. Announces Executive Changes
January 25, 2021 at 02:32 pm EST
Wuhan Hiteck Biological Pharma Co., Ltd. held its 1st Extraordinary General Meeting of 2021 on 22 January 2021, during which the following proposal(s) was/were approved: 1. Change of directors 1. Hou Pengyi. Change of independent directors, Ran Mingdong and Li Wenxin.
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024
Apr. 21
CI
Wuhan Hiteck Biological Pharma Co.,Ltd completed the acquisition of a 6.995% stake in Beijing Shadong Biotechnology Co., Ltd. from JunHe Enterprise Management Co., Ltd., Yang Shifang, Cui Junsheng, Sha Bingdong and Guo Cheng
Feb. 19
CI
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023
23-10-24
CI
Hiteck Biological Pharma Gets Nod to Trial Eye Drops
23-10-09
MT
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023
23-08-30
CI
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023
23-04-24
CI
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022
23-04-24
CI
Wuhan Hiteck Biological Pharma Co.,Ltd announced that it has received CNY 294.999985 million in funding from Nuode Asset Management Co., Ltd., Caitong Fund Management Co., Ltd., Shanghai Boshen Investment Center (Limited Partnership), Shenzhen Qianhai Eagle Fund Management Co., Ltd., UBS Group AG, Guodu Venture Capital Co., Ltd., and other investors
23-02-01
CI
Hiteck Biological Pharma Gets Regulatory Consent for Share Sale
23-01-23
MT
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022
22-10-24
CI
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022
22-08-02
CI
Wuhan Hiteck Biological Pharma Co.,Ltd announced that it expects to receive CNY 300 million in funding
22-05-17
CI
Wuhan Hiteck Biological Pharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
22-04-22
CI
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2021
22-04-22
CI
Wuhan Hiteck Biological Pharma Co.,Ltd Approves Board Appointments
21-12-13
CI
Wuhan Hiteck Biological Pharma Co.,Ltd agreed to acquire additional 6.9416% stake in Beijing Shadong Biotechnology Co., Ltd. from Beijing Zhongguancun VC Development Co., Ltd.
21-11-14
CI
Wuhan Hiteck Biological Pharma Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
21-10-28
CI
Wuhan Hiteck Biological Pharma : Bio-Pharma Nets $91 Million From Private Placement
21-10-14
MT
Wuhan Hiteck Biological Pharma Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
21-08-25
CI
Wuhan Hiteck Biological Pharma Co., Ltd. announced that it has received CNY 599.972 million in funding from a group of investors
21-08-03
CI
Xiweiai Pharmaceutical Technology Co., Ltd. announced that it expects to receive CNY 30 million in funding from Wuhan Hiteck Biological Pharma Co.,Ltd
21-07-20
CI
Wuhan Hiteck Biological Pharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
21-04-22
CI
Wuhan Hiteck Biological Pharma Co., Ltd. Announces Executive Changes
21-01-25
CI
Wuhan Hiteck Biological Pharma Co.,Ltd intends to acquire a 67% stake in Xiamen Weijia Pharmaceutical Co., Ltd. from Yongxin County Xinxinyuan Enterprise Management Consulting Center (Limited Partnership) for CNY 70.01 million.
20-11-12
CI
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2020
20-10-26
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Wuhan Hiteck Biological Pharma Co Ltd is a biopharmaceutical company. The Company operates five segments. The Biopharmaceutical segment is engaged in research, development, production and sales of biological products, and its primary product is mouse nerve growth factor for injection named Jinlujie. The Medical Technology Service segment is mainly involved in the technical development, technical consultation and technology transfer of chemical drugs. The In Vitro Diagnostic Reagents segment operates the research, development, production and sales of in vitro diagnostic reagents. The Pharmaceutical Sales and Wholesale segment is engaged in the sales and wholesale of pharmaceuticals. The Other segmentâs businesses include the cultivation and sales of Chinese herbal medicines, and the wholesale and retail of health products.
More about the company
1st Jan change
Capi.
-41.40% 383M +55.32% 819B -6.75% 351B +13.56% 329B +10.68% 298B +16.57% 242B +2.04% 225B +13.31% 217B +8.48% 168B -2.81% 158B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1